Table 1.
Characteristics of patients
| Number of patients (n = 37) |
Autologous PBSCT group II (n = 13) | Allogeneic BMT group III (n = 24) |
|---|---|---|
| Mean age (years) | 48.15 ± 12.67b | 36.00 ± 16.08 |
| Male | 10 | 12 |
| Female | 03b | 12 |
| Diagnosis | ||
| Multiple myeloma | 03 | 01 |
| Lymphoma Hodgkin | 05 | 03 |
| Lymphoma No Hodgkin | 02 | 02 |
| Leukemia | ||
| Leukemia Acute myeloid | 01 | 02 |
| Leukemia Chronic myeloid | 00 | 07 |
| Leukemia Acute lymphoblastic | 01 | 01 |
| Leukemia Chronic lymphoid | 00 | 01 |
| Myelodysplasia | 00 | 05 |
| Aplastic anemia | 00 | 02 |
| Tumor Ewing | 01 | 00 |
| Conditioning regimen | ||
| BuCy 120 | 01 | 13 |
| BuCy 200 | 01 | 00 |
| M-200 | 04 | 01 |
| CBV | 04 | 00 |
| FluCy | 00 | 05 |
| BEAM | 02 | 00 |
| CyTBI | 01 | 03 |
| another | 00 | 02 |
The CR patients were divided according to diseases. M-200: melphalan (200 mg/m2) given only 1 day (day minus 3) before the transplantation for multiple myeloma in autologous peripheral blood stem cell transplantation (PBSCT) or allogeneic BMT. CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU – 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 – 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU – 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 – 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT. FluCy: fludarabine (30 mg/m2) + cyclophosphamide (300 mg/m2), both given 3 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 2) for Hodgkin and non-Hodgkin lymphomas in allogeneic BMT. BuCy120: busulphan (1 mg/kg), given 4 consecutive days four times a day, starting 8 days before the transplantation (days minus 8 to minus 5) + cyclophosphamide (60 mg/kg), given 2 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 3) for acute and chronic myeloid leukemia and syndrome mielodysplastic in autologous PBSCT or allogeneic BMT. BuCy200: busulphan (1 mg/kg), given 3 consecutive days four times a day, starting 9 days before the transplantation (days minus 9 to minus 7) + cyclophosphamide (50 mg/m2), given 4 consecutive days, starting 6 days before the transplantation (days minus 6 to minus 3) for aplastic anemia in allogeneic BMT. CyTBI: cyclophosphamide (60 mg/m2), given 2 consecutive days, starting 7 days before the transplantation (days minus 7 to minus 6) + total body irradiation, carried out on 4 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 2, three times a day and day minus 1, two times a day) for acute and chronic lymphoid leukemia in autologous PBSCT or allogeneic BMT. All patients had 2 rest days (without chemotherapy) before the transplantation (days minus 2 and minus 1), except FluCy and CyTBI CR patients, that had only one rest day (day minus 1 and minus 5, respectively).
b Significantly different between groups II (autol.) and III (allog.).